Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.
Hiligsmann
Mickaël
M
HEC-ULg Management School, University of Liège, Liège, Belgium. m.hiligsmann@ulg.ac.be
Reginster
Jean-Yves
JY
D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001530:Belgium / Q000453:epidemiology; D050071:Bone Density Conservation Agents / Q000191:economics* / Q000627:therapeutic use*; D003198:Computer Simulation; D003362:Cost-Benefit Analysis / Q000191:economics; D000069448:Denosumab; D005260:Female; D050723:Fractures, Bone / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008390:Markov Chains; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000191:economics*; D019057:Quality-Adjusted Life Years; D053245:RANK Ligand / Q000191:economics* / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D053245:RANK Ligand; D000069448:Denosumab